This company listing is no longer active
AKUS Stock Overview
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Akouos, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$13.29 |
52 Week High | US$13.60 |
52 Week Low | US$2.32 |
Beta | -0.56 |
1 Month Change | 1.22% |
3 Month Change | 270.20% |
1 Year Change | 50.34% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -39.59% |
Recent News & Updates
Recent updates
Is Akouos (NASDAQ:AKUS) In A Good Position To Deliver On Growth Plans?
Sep 19Akouos stock rises 11% on FDA nod to start gene therapy trial for hearing loss
Sep 13We Think Akouos (NASDAQ:AKUS) Needs To Drive Business Growth Carefully
Jun 04We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth
Feb 19Companies Like Akouos (NASDAQ:AKUS) Are In A Position To Invest In Growth
Oct 28Here's Why We're Not Too Worried About Akouos' (NASDAQ:AKUS) Cash Burn Situation
Jun 26Akouos names Kathy Reape as chief development officer
May 07We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth
Mar 04Did Akouos, Inc. (NASDAQ:AKUS) Insiders Buy Up More Shares?
Jan 10Akouos (NASDAQ:AKUS) Is In A Good Position To Deliver On Growth Plans
Nov 18Shareholder Returns
AKUS | US Biotechs | US Market | |
---|---|---|---|
7D | 0.9% | -4.2% | -3.7% |
1Y | 50.3% | -2.0% | 20.5% |
Return vs Industry: AKUS exceeded the US Biotechs industry which returned -10.3% over the past year.
Return vs Market: AKUS exceeded the US Market which returned -16.1% over the past year.
Price Volatility
AKUS volatility | |
---|---|
AKUS Average Weekly Movement | 27.9% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.4% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AKUS's share price has been volatile over the past 3 months.
Volatility Over Time: AKUS's weekly volatility has increased from 20% to 28% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 103 | Manny Simons | www.akouos.com |
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company’s precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene.
Akouos, Inc. Fundamentals Summary
AKUS fundamental statistics | |
---|---|
Market cap | US$491.02m |
Earnings (TTM) | -US$92.59m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.3x
P/E RatioIs AKUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AKUS income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$92.59m |
Earnings | -US$92.59m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -2.51 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did AKUS perform over the long term?
See historical performance and comparison